Topic summary

Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists

Compounds › Cagrilintide & amylin analogues effect size cagrilintide cagrisema amylin analogues randomised trial

This is a generated summary. It shows the 8 most-liked posts from a topic of 54, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

chromatogramTL4Analytical chemist4 Jul 2025#3

NLoughran, post #1: Posting this under the heading it deserves: Nausea profile of amylin analogues compared with GLP-1 agonists Everything below is what sits behind that. Nausea profile of amylin analogues — I have the observation and I do not trust my interpretation of it, so I am posting the observation and holding the interpretation back. Numbers,… Go to post

Narrowing the opening post, because the general version has more than one answer.

Native amylin has awkward physical properties — it aggregates readily, which is why a stable analogue is a pharmaceutical achievement rather than a formulation detail.

The short answer was in the first line; everything after is the working.

21 likes in reply to #1 13mo

e.mensaTL26 Jul 2025#16

On analysis: an amylin analogue and its aggregates are not equally detectable by a standard reversed-phase method, because a large aggregate may not elute at all. Area percent cannot see what stays on the column.

I checked the source rather than the summary, and they differ.

26 likes 13mo

BBramleyTL3Regular7 Jul 2025#19

taper_table, post #13: Post #9 describes the usual case. This is about the unusual one. Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection. Go to post

Comparing an amylin analogue to an incretin agonist on weight change alone misses that they were developed to be used together rather than instead of each other.

The step people skip is the one I have spelled out.

20 likes in reply to #13 13mo

WendelboeTL2Member7 Jul 2025#21

This follows post #18 rather than contradicting it.

What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs over months or years, safety profile in populations not enrolled in the trials.

The evidence for this is thinner than the way I have phrased it suggests.

28 likes 13mo

cohort_driftTL3Regular9 Jul 2025#36

l.chevalier, post #15: Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a substantially different proposition and data from that is more relevant than data from pramlintide. I would put a moderate confidence on that and no more. Go to post

Taking post #35 at face value and following it one step further.

Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.

If anyone has run this properly I would rather read that than my own guess.

30 likes in reply to #15 13mo

f.fonsecaTL210 Jul 2025 · edited#40

NLoughran, post #29: Nausea profile of amylin analogues has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet. Go to post

Agreed on Nausea profile of amylin analogues, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and the starting assumption is the part nobody states.

22 likes in reply to #29 13mo

p.trevinoTL210 Jul 2025#44

Practical experience of Nausea profile of amylin analogues, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it interpretable.

22 likes 13mo

ni.stanescuTL211 Jul 2025#52

Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a substantially different proposition and data from that is more relevant than data from pramlintide.

21 likes 13mo

Read the full topic (54 posts)

Moved from Oral incretins by hana.sato. Category placement is not obvious from outside and getting it wrong is expected. This topic will get better answers here. The move is recorded in the public log citing R7.

Suggested topics

Topic	Participants	Replies	Views	Activity
Amylin analogue mechanism: satiety signalling separate from GLP-1 Compounds › Cagrilintide & amylin analogues effect size randomised trial cagrilintide cagrisema Solved Amylin analogue mechanism: satiety signalling separate from GLP-1 — setting out what I have, and where I think it stops being reliable. Trying to work out what would count as evidence on amylin analogue…	+128	142	38k	13mo
Why cagrilintide alone is discussed so much less than in combination Compounds › Cagrilintide & amylin analogues effect size amylin analogues cagrisema Solved Closed Why cagrilintide alone is discussed so much less than in combination I have a specific reason for asking rather than idle curiosity, and the context is below. Collecting what is known about cagrilintide alone…	+93	108	35k	16mo
About the Cagrilintide & amylin analogues category Compounds › Cagrilintide & amylin analogues cagrilintide cagrisema amylin analogues Pinned Wiki Long-acting amylin analogues alone and in combination. Mechanism, published data, and the open questions. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…		4	1.8k	11mo
Cagrilintide molecular characteristics and analytical considerations Compounds › Cagrilintide & amylin analogues cagrilintide randomised trial amylin analogues cagrisema Cagrilintide molecular characteristics and analytical considerations — setting out what I have, and where I think it stops being reliable. A methods question rather than a substantive one, about cagrilintide…		4	41k	12mo
Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it Compounds › Cagrilintide & amylin analogues cagrisema effect size randomised trial Wiki On the subject in the title: Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it Working notes rather than a conclusion. A comparison question rather than a question about one…	+2	6	2.4k	7mo

Related topics — sharing the tags effect size, cagrilintide, cagrisema

Topic	Participants	Replies	Views	Activity
Journal club: SELECT, absolute risk, and how it was reported — a second dataset Evidence › Journal club risk of bias effect size randomised trial journal club On the subject in the title: Journal club: SELECT, absolute risk, and how it was reported — a second dataset Working notes rather than a conclusion. Posting a small dataset on SELECT. It is mine, it is…		4	1.3k	1mo
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Compounds › Tirzepatide tirzepatide SURPASS programme effect size randomised trial Closed Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Writing it up because I had to work it out twice and would rather nobody else did. I would like to know what people here…	+89	101	32k	8mo
What a statistical analysis plan adds that the paper does not Evidence › Trials open label discontinuation & dropout randomised trial surrogate endpoints Solved What a statistical analysis plan adds that the paper does not — that is the question, and I have not found it answered plainly anywhere I have looked. Statistical analysis plan, and specifically the version…		2	6.6k	10h
Blinding yourself: practical methods and their limits Research Methods › N-of-1 designs confounding data table effect size On the subject in the title: Blinding yourself: practical methods and their limits Working notes rather than a conclusion. A methods question rather than a substantive one, about blinding yourself. Everyone…	+40	44	33k	5d
Run-in periods and the population they select Evidence › Trials surrogate endpoints discontinuation & dropout estimand randomised trial On the subject in the title: Run-in periods and the population they select Working notes rather than a conclusion. An honest uncertainty about run-in periods rather than a disguised assertion. I do not know…	+130	142	7.3k	1mo